Literature DB >> 32864503

Classification of Metal-based Drugs According to Their Mechanisms of Action.

Eszter Boros1, Paul J Dyson2, Gilles Gasser3.   

Abstract

Metal-based drugs and imaging agents are extensively used in the clinic for the treatment and diagnosis of cancers and a wide range of other diseases. The current clinical arsenal of compounds operate via a limited number of mechanisms, whereas new putative compounds explore alternative mechanisms of action, which could potentially bring new chemotherapeutic approaches into the clinic. In this review, metal-based drugs and imaging agents are characterized according to their primary mode of action and the key properties and features of each class of compounds are defined, wherever possible. A better understanding of the roles played by metal compounds at a mechanistic level will help to deliver new metal-based therapies to the clinic, by providing an alternative, targeted and rational approach, to supplement non-targeted screening of novel chemical entities for biological activity.

Entities:  

Year:  2019        PMID: 32864503      PMCID: PMC7451962          DOI: 10.1016/j.chempr.2019.10.013

Source DB:  PubMed          Journal:  Chem            Impact factor:   22.804


  89 in total

1.  Inorganic chemical biology: from small metal complexes in biological systems to metalloproteins.

Authors:  Sheila S David; Eric Meggers
Journal:  Curr Opin Chem Biol       Date:  2008-04-15       Impact factor: 8.822

Review 2.  A categorization of metal anticancer compounds based on their mode of action.

Authors:  Teresa Gianferrara; Ioannis Bratsos; Enzo Alessio
Journal:  Dalton Trans       Date:  2009-06-05       Impact factor: 4.390

3.  Radioactive Main Group and Rare Earth Metals for Imaging and Therapy.

Authors:  Thomas I Kostelnik; Chris Orvig
Journal:  Chem Rev       Date:  2018-10-31       Impact factor: 60.622

4.  Exploration of the medical periodic table: towards new targets.

Authors:  Nicolas P E Barry; Peter J Sadler
Journal:  Chem Commun (Camb)       Date:  2013-06-07       Impact factor: 6.222

5.  Aminoferrocene-based prodrugs activated by reactive oxygen species.

Authors:  Helen Hagen; Paul Marzenell; Elmar Jentzsch; Frederik Wenz; Marlon R Veldwijk; Andriy Mokhir
Journal:  J Med Chem       Date:  2012-01-11       Impact factor: 7.446

6.  Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?

Authors:  Reece G Kenny; Celine J Marmion
Journal:  Chem Rev       Date:  2019-01-14       Impact factor: 60.622

Review 7.  Satraplatin: leading the new generation of oral platinum agents.

Authors:  Ashish Bhargava; Ulka N Vaishampayan
Journal:  Expert Opin Investig Drugs       Date:  2009-11       Impact factor: 6.206

Review 8.  Carbon monoxide in biology and medicine.

Authors:  Stefan W Ryter; Leo E Otterbein
Journal:  Bioessays       Date:  2004-03       Impact factor: 4.345

Review 9.  New Designs for Phototherapeutic Transition Metal Complexes.

Authors:  Cinzia Imberti; Pingyu Zhang; Huaiyi Huang; Peter J Sadler
Journal:  Angew Chem Int Ed Engl       Date:  2019-09-24       Impact factor: 16.823

10.  Exploring Oxidovanadium(IV) Complexes as YopH Inhibitors: Mechanism of Action and Modeling Studies.

Authors:  Priscila G A Martins; Mattia Mori; Louise D Chiaradia-Delatorre; Angela C O Menegatti; Alessandra Mascarello; Bruno Botta; Julio Benítez; Dinorah Gambino; Hernán Terenzi
Journal:  ACS Med Chem Lett       Date:  2015-08-31       Impact factor: 4.345

View more
  26 in total

1.  Enzyme Control Over Ferric Iron Magnetostructural Properties.

Authors:  Huan Wang; Michael B Cleary; Luke C Lewis; Jeffrey W Bacon; Peter Caravan; Hannah S Shafaat; Eric M Gale
Journal:  Angew Chem Int Ed Engl       Date:  2021-12-02       Impact factor: 15.336

Review 2.  Potential Application of Photosensitizers With High-Z Elements for Synergic Cancer Therapy.

Authors:  Paromita Sarbadhikary; Blassan P George; Heidi Abrahamse
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

Review 3.  Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs.

Authors:  Jingjing Huang; Weize Ding; Xingfan Zhu; Bingbing Li; Fangang Zeng; Kui Wu; Xiaoqin Wu; Fuyi Wang
Journal:  Front Chem       Date:  2022-06-09       Impact factor: 5.545

4.  Dose Uptake of Platinum- and Ruthenium-based Compound Exposure in Zebrafish by Inductively Coupled Plasma Mass Spectrometry with Broader Applications.

Authors:  Brittany F Karas; Cathleen L Doherty; Kristin R Terez; Leonor Côrte-Real; Keith R Cooper; Brian T Buckley
Journal:  J Vis Exp       Date:  2022-04-21       Impact factor: 1.424

Review 5.  Metal Complexes as Antiviral Agents for SARS-CoV-2.

Authors:  Johannes Karges; Seth M Cohen
Journal:  Chembiochem       Date:  2021-06-14       Impact factor: 3.461

Review 6.  Rational approaches towards inorganic and organometallic antibacterials.

Authors:  Jeannine Hess
Journal:  Biol Chem       Date:  2021-07-13       Impact factor: 4.700

Review 7.  Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments.

Authors:  Damiano Cirri; Francesco Bartoli; Alessandro Pratesi; Emma Baglini; Elisabetta Barresi; Tiziano Marzo
Journal:  Biomedicines       Date:  2021-05-04

8.  Ligand-centred redox activation of inert organoiridium anticancer catalysts.

Authors:  Wen-Ying Zhang; Samya Banerjee; George M Hughes; Hannah E Bridgewater; Ji-Inn Song; Ben G Breeze; Guy J Clarkson; James P C Coverdale; Carlos Sanchez-Cano; Fortuna Ponte; Emilia Sicilia; Peter J Sadler
Journal:  Chem Sci       Date:  2020-05-15       Impact factor: 9.825

9.  Cavity-Containing [Fe2L3]4+ Helicates: An Examination of Host-Guest Chemistry and Cytotoxicity.

Authors:  Lynn S Lisboa; Mie Riisom; Roan A S Vasdev; Stephen M F Jamieson; L James Wright; Christian G Hartinger; James D Crowley
Journal:  Front Chem       Date:  2021-07-07       Impact factor: 5.221

Review 10.  Rhenium-Based Complexes and in Vivo Testing: A Brief History.

Authors:  Miles S Capper; Hollie Packman; Mark Rehkämper
Journal:  Chembiochem       Date:  2020-04-14       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.